Faculty Collaboration Database -

CURRICULUM VITAE

Paul D. Harker-Murray MD, PhD

Professor
Department of Pediatrics
Division of Hematology and Oncology - Pediatrics


OFFICE ADDRESS:
MACC Fund Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226


EDUCATION:
09/1989 - 05/1993 BS-Psychology, University of Michigan, Ann Arbor, MI
05/1993 - 05/2001 MD, Mayo Medical School, Mayo Clinic & Foundation, Rochester, MN
05/1993 - 05/2001 PhD, Mayo Graduate School, May Clinic & Foundation, Rochester, MN
2013 - 2014 Faculty Scholar Program in Quality & Safety, Medical College of Wisconsin, Milwaukee, WI


POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
06/2001 - 06/2004 Internship and Residency in Pediatrics, Pediatrics, University of Minnesota, Children's Hospital Minneapolis, 2450 Riverside Avenue, Minneapolis, MN 55454
07/2004 - 09/2007 Postdoctoral Fellowship, Pediatrics, Hematology/Oncology/BMT, University of Minnesota, 2450 Riverside Avenue, 6th Floor, Minneapolis, MN 55454


FACULTY APPOINTMENTS:
11/01/2001 - 07/15/2013 Assistant Professor, Pediatrics, Hematology/Oncology/BMT, University of Texas, Southwestern Medical Center in Dallas, 1801 Inwood Road, Dallas, TX 75235
08/2013 - 06/2016 Assistant Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, 8701 Watertown Plank Road, MFRC 3018, Milwaukee, WI 53226
07/2016 - Present Associate Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226


EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
2010 - 2013 Education Coordinator for Hematology, Oncology, Bone Marrow Transplant, Children's Medical Center, 1935 Medical Center Drive, Dallas, TX 75235
2015 - Present Director of Resident Education for Hematology, Pediatrics, Hematology/Oncology/Bone Marrow Transplant, Children's Hospital of Wisconsin, 9000 W Wisconsin Avenue, Milwaukee, WI 53226


HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
2014 - Present Hospital Acquired Condition (HAC) leader. Invited position., Children's Hospital of Wisconsin, Milwaukee, WI
2014 - Present Value champion: Oversee all quality improvement initiatives, Hematology, Oncology, Bone Marrow Transplantation, Pediatrics, Milwaukee, WI
2014 - 2015 Leader: Clinical Documentation Improvement group of Operational and Financial Stewardship core team, Children's Hospital of Wisconsin, Milwaukee, WI
2014 - 2015 Operational and Financial Stewardship core team, Invited Member, Children's Hospital of Wisconsin, Milwaukee, WI
2017 - Present Epic Provider Clinical Documentation Improvement, Children's Hospital of Wisconsin, Milwaukee, WI 53226
2018 - Present Medical Director, Pediatrics, Hematology/Oncology/BMT Clinical Trials Office
2018 - Present EPIC Provider Cabinet GroupAd Hoc committee to make decisions regarding updates to the electronic medical record that affect multiple areas of care, Children's Hospital of Wisconsin
2021 - Present CHW Medical Staff Section Chief for Hematology, Oncology and Bone Marrow Transplant, elected position, Hematology, Oncology and Bone Marrow Transplant, Children's Hospital Wisconsin
2023 - 2024 Neuro-Oncology Program Director
2023 - Present Oncology Program Director, Interim
2024 - Present Invited Member of the Cancer Center's Clinical Research Executive Committee


RESEARCH ADMINISTRATIVE APPOINTMENTS:
2016 - Present Institutional Principle Investigator for all Children's Oncology Group (COG) Clinical trials, Pediatrics, Hematology, Oncology, Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI


HOSPITAL STAFF PRIVILEGES:
12/04/2007 - 07/15/2013 Pediatrics, Hematology/Oncology/BMT, Children's Medical Center, 1935 Medical Center Drive, Dallas, TX 75235
12/04/2007 - 07/15/2013 Pediatrics, Hematology/Oncology/BMT, St. Paul University Hospital - UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75235
12/04/2007 - 07/15/2013 Pediatrics, Hematology/Oncology/BMT, Parkland Health & Hospital System, 5201 Harry Hines Blvd, Dallas, TX 75235
08/01/2013 - Present Active, Pediatrics, Hematology/Oncology/BMT, Children's Hospital of Wisconsin, 9000 W. Wisconsin Avenue, Wauwatosa, WI 53226


SPECIALTY BOARDS AND CERTIFICATION:


Board Certified	Issue Date	Expiration
Pediatric Hematology/Oncology	2009	None


Licensure	Number	Issue Date	Expiration
Medicine and Surgery	61047-20	07/09/2013	10/31/2021


AWARDS AND HONORS:
1992 Gold Key Honor Society, University of Michigan
1992 David Bohr Research Fellowship Award
1999 Outstanding Young Leader Award, Zumbro Valley Medical Society
2000 Keynote Speaker at Gamehaven Council of the BSA Annual Eagle Recognition and Alumni Dinner, Boy Scouts of America
2000 Lyle Weed, MD Healthy Community Award, Olmstead County Public Health Services
2004 Susan Vincent Outstanding Resident Teaching Award
2010 Excellence in Education Medical Student Clinical Teaching Award, UT Southwestern
2011 Advocacy Mentor Award, UT Southwestern
2013 Dr. George Buchanan Teaching Award for Excellence in Fellow Education
2013 Faculty Teacher of the Year Award, Children's Medical Center Pediatric Residency
2014 Mobile App Challenge Winner
2018 MCW Cancer Center Outstanding Achievement Award in Pediatric Clinical Research, Medical College of Wisconsin Cancer Center
2018 Winner – Pediatric Resident Summer Olympics (month long time-based exercise challenge)
2020 Winner – Pediatric Resident Summer Olympics (month long time-based exercise challenge)


MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
American Society of Clinical Oncology (Member)
Children's Oncology Group (Member)
American Society of Pediatric Hematology and Oncology (Member)
American Society of Hematology (Member)


EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorship
2014 - 2018 Young Investigator abstracts
2015 Clinical Research Associates
2022 - Present Editorial Board of Adolescent and Young Adult Oncology (specialty section of Frontiers in Adolescent Medicine).
2023 - Present Editorial Board of Frontiers in Immunology, Issue Cancer Immunity and Immunotherapy
Journal Review
2013 - 2019 Journal of Pediatric Hematology and Oncology (2013, 2014, 2015, 2017, 2018, 2019 x7)
2014 Leukemia and Lymphoma
2015 - 2018 Pediatric Blood and Cancer (2015, 2016 x2, 2018 x2)
2017 Journal of Pulmonary Medicine
2020 Pediatric Research
2020 Blood
2020 Journal of the National Comprehensive Cancer Network


NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2012 - Present Member, Children's Oncology Group Young Investigator Committee, Children's Oncology Group
2012 - Present Member, Children's Oncology Group Hodgkin Lymphoma Retrieval Subcommittee, Children's Oncology Group
2012 - Present Member, Children's Oncology Group Hodgkin Lymphoma Committee, Children's Oncology Group
2012 - Present Member, Children's Oncology Group Hodgkin Lymphoma Steering committee, Children's Oncology Group
2014 - Present Member, Children's Oncology Group Langerhans Cell Histiocytosis Subcommittee of the Non-Hodgkin lymphoma committee, Children's Oncology Group
2014 - Present One of 12 pediatric oncologist selected from a national pool, Epic Pediatric Oncology Steering Board
2015 - Present Course Co-chair, Board Review, American Society of Pediatric Hematology and Oncology
2016 - Present Invited by Daniel Hayes, MD, FASCO, President-Elect of ASCO to serve as member, Cancer Education Committee, Pediatric Oncology Track, American Society of Clinical Oncology (ASCO)
2016 - Present Member, Solution for Patient Safety (SPS) Hematology and Oncology CLABSI Reduction Workgroup, National collaboration among >30 Children's Hospitals
2016 - Present Appointed Member, Study Committee ANHL1522, Children’s Oncology Group
2017 - Present Chairperson, Epic Pediatric Oncology Steering Board, EPIC
2017 - Present Chairperson, Epic Pediatric Oncology Steering Board, nominated and elected by colleagues on the steering board 2017. Lead team to develop improved functionality of EPIC
2017 - Present liaison from the ASPHO Review Course Committee, American Society of Pediatric Hematology and Oncology (ASPHO) Education Committee, American Society of Pediatric Hematology and Oncology (ASPHO)
2017 - 2020 Elected Position, American Society of Pediatric Hematology and Oncology Nominating Committee, American Society of Pediatric Hematology and Oncology
2020 Participant, Accreditation Subcommittee reaccreditation meetings to ensure ASPHO complies with ACCME guidelines, American Society of Pediatrics Hematology and Oncology (ASPHO)
2021 - Present Vice Chair, Children’s Oncology Group lymphoblastic lymphoma subcommittee
2022 - Present Lead for development of up-front clinical trials in Pediatric, Adolescent and Young Adult Hodgkin Lymphoma through the Children’s Oncology Group
2023 - Present Acting Director, Pediatric Neuro-Oncology Program, Medical College of Wisconsin
2024 - Present Invited Member, Children's Oncology Group Study Committee

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:


Active
Peer Review
Title:	AHOD1721: Risk-adapted, response-based, Phase II open-label trial of nivolumab + brentuximab vendotin for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma who have failed first-line therapy, followed by brentuximab + bendamustine for participants with a suboptimal response.
Source:	Children's Oncology Group and with international collaboration with EuroNET
Role & Effort:	Trial concept, design, and Principal Investigator
PI:	Paul Harker-Murray
Dates:	2012 - Present

Title:	Use of Computerized Physician Order Entry (CPOE) reduces provider chemotherapy errors in pediatric oncology center
Role & Effort:	Institutional Principle Investigator
PI:	Paul Harker-Murray, MD
Dates:	2012 - Present

Title:	Phase 1 Dose-escalating Study of MM-398 (Nanoliposomal Irinotecan) plus Intravenous Clycophosphamide in Recurrent or Refractory Pediatric Solid Tumors.
Source:	South Plains Oncology Consortium (SPOC)
Role & Effort:	Protocol Chairperson/Principle Investigator
Dates:	2012 - Present

Title:	ALTE11C1 - Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
Source:	Children’s Oncology Group
Role & Effort:	Institutional Principle Investigator
Dates:	2014 - Present

Title:	ACCL0922 - A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
Source:	Children’s Oncology Group
Role & Effort:	Institutional Principle Investigator
Dates:	2014 - Present

Title:	Phase II Brentuximab Vedotin or Crizotinib with Chemotherapy for Newly Diagnosed ALCL
Source:	Children’s Oncology Group
Role & Effort:	Institutional Principle Investigator
Dates:	2014 - Present

Title:	COG-APEC14B1. The project everychild protocol: a registry, eligibility screening, biology and outcome study
Source:	Children’s Oncology Group
Role & Effort:	Institutional Principle Investigator
Dates:	2016 - Present

Title:	ACCL1333/CV185155: A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated Asparaginase
Source:	Children’s Oncology Group
Role & Effort:	Institutional Principle Investigator
Dates:	2016 - Present

Title:	Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20+ Mature B-Cell Lymphoma Protocol Type: Treatment
Role & Effort:	Institutional Principle Investigator
Dates:	2016 - Present

Title:	AOST1421 A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
Source:	Children’s Oncology Group
Role & Effort:	Institutional Principle Investigator
Dates:	2016 - Present


Prior
Peer Review
Title:	Research on the effect of Ramipril on vascular activity, changes associated with atherosclerosis-induced diabetes in rabbits
Source:	University of Michigan Physiology Department
Role & Effort:	Laboratory Research
Dates:	05/1991 - 09/1991

Title:	Characterization of the role of endothelium in vascular activity in streptozotocin-induced diabetes in rats."
Source:	University of Michigan, Physiology Department
Role & Effort:	Laboratory Research
Dates:	09/1991

Title:	Ramipril prevents hypersensitivity to phenylephrine in aorta from streptozotocin-induced diabetic rats.
Source:	University of Michigan, Physiology Department
Role & Effort:	Laboratory Research
Dates:	05/1992 - 09/1992

Title:	Comparing the insulin sensitizing agent CS-045 with angiotensin-converting enzyme inhibitor quinapril, on insulin resistance in spontaneously hypertensive rats.
Source:	Grant
Role & Effort:	Investigator
Dates:	09/1992 - 12/1992

Title:	Immune effectors of resistance to demyelination and neurologic disease in a viral model of multiple sclerosis.
Source:	Mayo Graduate School, Department of Immunology
Role & Effort:	Laboratory Research/Doctoral Thesis
Dates:	1995 - 2000

Title:	Evaluating the methodological quality of clinical practice guidelines for the treatment of patients with diabetes mellitus.
Source:	Mayo Clinic and Foundation Research, Department of Internal Medicine, Division of Endocrinology
Role & Effort:	Investigator
Dates:	10/2000

Title:	Developing novel methods of inducing human naive CD4+ T cells to differentiate into CD4+D25+FoxP3+ regulatory T cells and study of in vivo function of human regulatory T cell function.
Source:	Pediatric Hematology/Oncology and Blood and Bone Marrow Transplantation
Role & Effort:	Laboratory Research
Dates:	2005 - 2007

Title:	Open Label Bendamustine for Pediatric Patients with Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes.
Source:	Cephalon, Inc
Role & Effort:	Institutional Primary Investigator
PI:	Paul Harker-Murray, MD
Dates:	2011 - 2012

Title:	Randomized, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming with Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects.
Source:	Eisai
Role & Effort:	Institutional Principal Investigator
PI:	Paul Harker-Murray, MD
Dates:	2011 - 2012

Title:	An open-label, cross-over, pharmacokinetic study to assess the safety and pharmacokinetics of transdermal granisetron (SancusoR patch) and IV granisetron in a pediatric oncology population (aged 2 to 5 years).
Source:	Strakan Pharmaceuticals Ltd
Role & Effort:	Institutional Primary Investigator
PI:	Paul Harker-Murray, MD
Dates:	2012 - 2013

Title:	An open-label, cross-over, pharmacokinetic study to assess the safety and pharmacokinetics of transdermal granisetron (SancusoR patch) and IV granisetron in a pediatric oncology population (aged 6 to 12 years).
Source:	Strakan Pharmaceuticals Ltd
Role & Effort:	Institutional Primary Investigator
PI:	Primary Investigator
Dates:	2012 - 2013

Title:	Methylnaltrexone in Pediatric Populations: A Retrospective Chart Review. Supervising fourth year medical student, Stephanie Bezner.
Role & Effort:	Institutional Primary Investigator
PI:	Paul Harker-Murray, MD
Dates:	2012 - 2013

Title:	An open-label, cross-over, pharmacokinetic study to assess the safety and pharmacokinetics of transdermal granisetron (SancusoR patch) and IV granisetron in a pediatric oncology population (aged 13 to 17 years).
Source:	Strakan Pharmaceuticals Ltd
Role & Effort:	Institutional Primary Investigator
Dates:	2014 - Present


INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
International
Relapsed Hodgkin Lymphoma in Children: “How do we best stratify intensity of retrieval therapy?”, Children’s Oncology Group bi-annual meeting, 2013
Brentuximab vedotin and bendamustine for relapsed pediatric Hodgkin lymphoma, Children’s Oncology Group bi-annual meeting. Fall, 2014
Relapsed Hodgkin Lymphoma in Children: Proposal for a risk-stratified, response-based trial, Children’s Oncology Group bi-annual meeting. Spring, 2014
Incorporation of a PD-1 inhibitor into a clinical trial for Relapsed Hodgkin Lymphoma in Children: Proposal for a risk-stratified, response-based trial., Children’s Oncology Group bi-annual meeting. Spring, 2015
Nivolumab Followed by Chemotherapy for Relapsed Hodgkin Lymphoma in Children: Proposal for a risk-stratified, response-based trial., Children’s Oncology Group bi-annual meeting. Fall, 2015
Relapsed Hodgkin Lymphoma in Children: Proposal for a collaborative risk-stratified, response-based trial wiht COG and EuroNet., Children's Oncology Group B-Annual Meeting, 2016
Recent Advances in Pediatric and AYA Lymphomas. Children’s Oncology Group / American Society of Pediatric Hematology and Oncology Continuing Medical Education program, COG annual meeting., 2020

National
Harker-Murray, PH, Practical and Ethical Dilemmas in Cord Banking, 41st Kenneth C. Haltalin Pediatrics for the Practitioner Annual Seminar, 04/2009
Harker-Murray, PH, Pediatric Cancer - An Overview, The Southwest Center for Pediatric Environmental Health and Lake Country AHEC Conference on Children's Environmental Health, Paris, TX, 09/2009
Harker-Murray, PH, Review Course: Lymphoma, American Society of Pediatric Hematology and Oncology, 02/2011
Harker-Murray, PH, Practical Pediatric Hematology-Oncology 2011: Lymphadenopathy and Lymphoma, Children's Medical Center in conjunction with UTSW Department of Pediatrics, Dallas, TX, 11/2011
Harker-Murray, PH, The Efficacy of Umbilical Cord Stem Cells from Private and Public Cord Blood Banks: Present and Anticipated Future Clinical Utility, American College of Osteopathic Obstetricians and Gynecologists Meeting, Tucson, AZ, 03/2012
Hodgkin and non-Hodgkin Lymphoma, American Society of Pediatric Hematology and Oncology Pediatric Hematology and Oncology Board Review Course, Virtual, 01/2021
Response adapted chemoimmunotherapy Treatment of relapsed and refractory Hodgkin Lymphoma., Pediatric HEM/ONC Lecture Series, University of Miami Children's Hospital, 09/2024 - Present

Regional
Harker-Murray, PH, "What do YOU Think, Doctor, Should We Get It?" Antenatal Counseling on Stem Cell Cord Blood Collection, American College of Osteopathic Obstetricians and Gynecologists, Grapevine, TX, 10/2012

Local
Pesenter: Harker-Murray, Paul, Bandyopadhyay, S. et al, "Risk of serious bacterial infection in children with fever without a source in the post-haemophilus influenzae era when antibiotics are reserved for culture-proven bacteremia." Arch Pediatr Adolesc Med 2002; 156(5):512-517, University of Minnesota: Evidence-based Medicine Review, University of Minnesota, 2002
Harker-Murray, Paul, "A Brief Approach to Herbal Medical in the United States", University of Minnesota Department of Pediatrics Symposium on Complementary and Alternative Therapies, Minneapolis, MN, 2002
Harker-Murray, Paul, "Adherence of Published Diabetes Mellitus Practice Guidelines to Methodological Standards of Guideline Development, University of Minnesota, Pediatric Endocrinology, Minneapolis, MN, 2002
Harker-Murray, Paul, "Opportunities for Intervention in a Case of Acute Spinal Cord Injury", Hennepin County Medical Center, Department of Emergency Medicine Meeting, Minneapolis, MN, 2003
Harker-Murray, Paul, "Vaccine Safety", University of Minnesota, Department of Pediatrics, Minneapolis, MN, 2003
Harker-Murray, Paul, "A Critical Review of Intravenous Methylprednisolone in Acute Spinal Cord Injury", Combined Department of Emergency Medicine Meetings - Hennepin County Medical Center and Regions Hospital, St. Paul, MN, 2003
Harker-Murray, Paul, The Role of Hypertonic Saline in the Treatment of Elevated Intracranial Pressure, Department of Emergency Medicine Meeting at Hennepin County Medicine Center, Minneapolis, MN, 2003
Harker-Murray, Paul, "Neonatal Thrombocytopenia", Resident and Medical Student Lectures, University of Minnesota, Minneapolis, MN, 2004
Harker-Murray, Paul, "Pathology and Treatment of Acute Graft-Versus-Host Disease", Resident and Medical Staff Lectures, University of Minnesota Department of Pediatrics, Minneapolis, MN, 2004
Harker-Murray, Paul, "Hemoglobin Electrophoresis in the Diagnosis of Thalassemia", Residents and Medical Students Lectures, University of Minnesota, Minneapolis, MN, 2004
Harker-Murray, Paul, "Immune Reconstitution Following Bone Marrow Transplantation", Residents and Medical Students Lectures, University of Minnesota, Minneapolis, MN, 2004
Harker-Murray, Paul, "EBV+T Cell Posttransplant Lymphoproliferative Disorder in Children", "Pediatric Cancer and Blood Diseases Conference, University of Minnesota, Department of Pediatric Hematology and Oncology, Minneapolis, MN, 2004
Harker-Murray, Paul, "Poor Hematopoietic Recovery Following Induction Therapy for ALL." "Syndromes of Immunodeficiency and Macrophage Activation.", Pediatric and Blood Cancer Conference, University of Minnesota, Department of Pediatrics, Minneapolis, MN, 2005
Harker-Murray, Paul, "Meningitis in Bone Marrow Transplant Patients.", Pediatric Cancer and Blood Diseases Conference, University of Minnesota, Department of Pediatric Hematology and Oncology, Minneapolis, MN, 2005
Harker-Murray, Paul, "Nasopharyngeal Carcinoma in Pediatric Patients", Pediatric Cancer and Blood Diseases Conference, University of Minnesota, Department of Pediatrics, Minneapolis, MN, 2006
Harker-Murray, Paul, "Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Relapsed Acute Leukemia with and without CNS Involvement, 21st Annual Pediatric Research, Education, and Scholarship Symposium, Minneapolis, MN, 2007
Harker-Murray, Paul, "Metastatic Rhabdomyosarcoma", Pediatric Cancer and Blood Disease Conference, University of Minnesota, Department of Pediatrics, Minneapolis, MN, 2007
Harker-Murray, PH, Practical and Ethical Dilemmas in Cord Blood Banking, Practical Pediatric Hematology-Oncology 2008, Children's Medical Center in conjunction with UTSW Department of Pediatrics, Dallas, TX, 10/2008
Harker-Murray, PH, An Ethical Dilemma: A controversy in collecting umbilical cord blood for donation to a public bank, Pediatric Hematology/Oncology Grand Rounds, UT Southwestern, 02/2010
Harker-Murray, PH, Cord Blood Banking - Provider Responsibilities, UT Southwestern Maternal Fetal Medicine Lecture Series, UT Southwestern, 04/2011
Harker-Murray, PH, Umbilical Cord Blood Banking: a "safeguard for the future?", UT Southwestern Medical Center Pediatric Grand Rounds, Dallas, TX, 04/2012
Harker-Murray, PH, Practical Pediatric Hematology-Oncology 2008: Ethical Risks and Practical Benefits of Cord Blood Banking, Children's Medical Center in conjunction with UTSW Department of Pediatrics, Dallas, TX, 11/2012
Harker-Murray, PH, Hemophagocytic Lymphohistiocytosis, Multidisciplinary Case Conference, Children's Medical Center, Dallas, TX, 12/2012
Harker-Murray, PH, Fibrodysplasia Ossificans Progessiva, Multidisciplinary Case Conferences, Children's Medical Center, Dallas, TX, 01/2013
Harker-Murray, PH, Pediatric Oncology: Introducing a family to childhood cancer, Dallas Chapter of the American Academy of Professional Coders, Dallas, TX, 03/2013
Harker-Murray, PH, Common Symptoms and Intern Calls in Oncology - Preparation for Internship, Medical Student Elective, Dallas, TX, 03/2013
Toxic Epidermal Necrolysis in a child with Burkitt lymphoma, Multidisciplinary tumor board, Medical College of Wisconsin, Milwaukee, WI, 04/2014
Therapeutic options for low risk Wilms tumor, Multidisciplinary tumor board presentation, Medical College of Wisconsin, Milwaukee, WI, 05/2014
Checkpoint Inhibitors: Targetable pathways in pediatric Hodgkin and non-Hodgkin lymphomas, Multidisciplinary tumor board presentation, Medical College of Wisconsin, Milwaukee, WI, 08/2015
Checkpoint Inhibitors: Targetable pathways in pediatric Hodgkin and Non-Hodgkin lymphomas, Multidisciplinary Tumor Board Presentation, Medical College of Wisconsin, 08/2015
High risk Hodgkin Lymphoma in the Brentuximab Era, Multidisciplinary tumor board presentation, Medical College of Wisconsin, Milwaukee, WI, 09/2015
Methylnaltraxone for opioid induced constipation, Multidisciplinary tumor board presentation, Medical College of Wisconsin, Milwaukee, WI, 09/2015
Evaluation of Treatment Response in Pediatric Hodgkin Lymphoma., Multidisciplinary tumor board presentation, Medical College of WI, 05/2017
34. An International Trial for Relapsed Pediatric Hodgkin Lymphoma, Department of Pediatrics Grand Rounds, Children's Wisconsin, 05/2021
Development of An International Trial for Relapsed Pediatric Hodgkin Lymphoma, Connect to Purpose, 2023
33. Development of a clinical trial for relapsed Hodgkin lymphoma, Discovery and Developmental Research Forum, Medical College of Wisconsin
Development of an International Trial for Relapsed Pediatric Hodgkin Lymphoma, Connect to Purpose Speaker. Invited speaker to members of our Clinical Trials
Development of a clinical trial for relapsed Hodgkin lymphoma, Discovery and Developmental Research Forum, Medical College of WI


PEER REVIEWED WORKSHOPS/PRESENTATIONS:
National
Lymphoma., American Society of Pediatric Hematology and Oncology Pediatric Hematology and Oncology Board Review Course, 02/2011
Hodgkin and Non-Hodgkin Lymphoma., American Society of Pediatric Hematology and Oncology Pediatric Hematology and Oncology Board Review Course, 02/2013
Lymphoma, American Society of Pediatric Hematology and Oncology Board Review Course, 02/2015
Lymphoma, American Society of Pediatric Hematology and Oncology Board Review Course, 02/2017
Lymphoma, American Society of Pediatric Hematology and Oncology Pediatric Hematology and Oncology Board Review Course, 02/2019
Lymphoma, American Society of Pediatric Hematology and Oncology Pediatric Hematology and Oncology Board Review Course, 02/2019
Clinical Conundrums in Relapsed Hodgkin Lymphoma: Presentation and interactive discussion on Relapsed Hodgkin Lymphoma at the American Society of Pediatric Hematology and Oncology Annual Meeting, 05/2019
Lymphoma, American Society of Pediatric Hematology and Oncology Pediatric Hematology and Oncology Board Review Course, 02/2021
Clinical Conundrums in Pediatric Non-Hodgkin Lymphoma: Presentation and interactive discussion on Relapsed non-Hodgkin Lymphoma, The American Society of Pediatric Hematology and Oncology Annual Meeting, 05/2023
How We Do It®: Novel Biologic Strategies Reshaping Treatment Decision-Making in Pediatric to Adult Hodgkin Lymphoma, Invited speaker at ACCME accredited symposium on pediatric and adult Hodgkin Lymphoma, Fairmont Chicago, Millennium Park, 09/08/2023
How We Do It®: Novel Biologic Strategies Reshaping Treatment Decision-Making in Pediatric to Adult Hodgkin Lymphoma. Invited speaker, ACCME accredited symposium on pediatric and adult Hodgkin Lymphoma, Fairmount Chicago, Millennium Park, 09/08/2023
How We Do It®: Novel Biologic Strategies Reshaping Treatment Decision-Making in Pediatric to Adult Hodgkin Lymphoma., Invited speaker at ACCME accredited symposium on pediatric and adult Hodgkin Lymphoma, Virtual Webinar, 11/16/2023
Children’s Oncology Group Young Investigator Summer meeting. Interactive presentation on networking and involvement within COG
How We Do It: Novel Biologic Strategies Reshaping Treatment Decision-Making in Pediatric to Adult Hodgkin Lymphoma., Invited speaker at ACCME accredited symposium on pediatric and adult Hodgkin Lymphoma, Fairrmont Chicago, Millennium Park, - 09/08/2023
How We Do It: Novel Biologic Strategies Reshaping Treatment Decision-Making in Pediatric to Adult Hodgkin Lymphoma, Invited speaker at ACCME accredited symposium on pediatric and adult Hodgkin Lymphoma, (Webinar), - 11/16/2023


COMMITTEE SERVICE:
Medical College of Wisconsin
2008 - 2013 Member, Pediatric Residency Admissions Committee, Pediatrics, UT Southwestern
2010 - 2013 Officer, Billing Compliance, University of Texas Southwestern
2011 - 2013 Member, Fellowship Admissions Committed, Hematology/Oncology/BMT, Pediatrics, UT Southwestern
2012 - 2013 Member, Continuing Medical Education Committee, Pediatrics, University of Texas Southwestern
2012 - 2013 Physician Champion, Beacon Committee, Pediatrics, University of Texas Southwestern
2012 - 2013 Committee Member, Epic Implementation Committee, Pediatrics, University of Texas Southwestern
2012 - 2013 Oversight Physician, Clinical Research Office for the Center for Cancer and Blood Disorders, University of Texas Southwestern
2012 - 2013 Member, Chemotherapy Task Force, Pediatrics, University of Texas Southwestern
2013 - Present Member, Pediatric Intern Selection Committee, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
2013 - Present Chair, Hematology/Oncology/BMT Committee on Quality and Patient Saftey, Hematology/Oncology/BMT, Pediatrics, Children's Hospital of Wisconsin
2013 - Present Member, Faculty Scholar Program in Quality & Safety, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
2013 - Present Member, HOT Services Partnership Council, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
2013 - Present Member, Clinical Documentation Initiative to Improve Medical Communication, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
2013 - Present Member, Epic and Beacon Implementation, Pediatrics, Medical College of Wisconsin
2013 - Present Member, MACC Fund Design Core Team, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
2014 - Present Member, Pediatric Hematology/Oncology Fellowship Admission Committee, Medical College of Wisconsin
2014 - Present Invited Member, Clinical Competency Committee for Pediatric Hematology Fellows, Medical College of Wisconsin
2014 Member, The Clinical Research Seed Grant Review Committee, Medical College of Wisconsin
2020 - Present Present Invited Reviewer, Pilot Grant Applications, Cancer Center, Medical College of Wisconsin Cancer Center
2020 - Present Present Invited Reviewer, Pilot Grant Applications, Cancer Center, Medical College of Wisconsin
2020 - Present Invited position for prioritization and management of quality improvement initiative, Present Oncology Operations Council, Clinical Leadership Team
2023 - Present MCW Freedom of Expression Committee
2023 - Present Member, MCW Dept. of Pediatrics Diversity, Equity, and Inclusion Council
2024 - Present Member, Hodgkin Lymphoma National Pediatric Hematology/Oncology Advisory Board

Hospital
2013 - Present Member, Hematology/Oncology/BMT Services Partnership Council (Inpatient and Ambulatory QI and Clinical Practice, Hematology/Oncology/BMT, Pediatrics, Children's Hospital of Wisconsin
2013 - Present Member, Documentation Standards - Problem List Sub-committee, Hematology/Oncology/BMT, Pediatrics, Children's Hospital of Wisconsin
2013 - Present Participant/Member, Electronic Health Record Committee Sub-Group (to develop recommendations around medical staff documentation standards and problem list use and etiquette), Pediatrics, Medical College of Wisconsin
2013 - Present Member, Leukemia and Lymphoma Committee, Children's Hospital of Wisconsin
2014 - Present Member, Supportive Care & Cancer Control committee, Children's Hospital of Wisconsin
2014 - Present Member, Catheter Line Associated Blood stream Infection (CLABSI) Safety Improvement Team, Children's Hospital of Wisconsin
2014 - Present Member, Developmental Therapeutics committee, Children's Hospital of Wisconsin
2014 - Present Member, CLABSI subgroup of Solution for Patient Safety (SPS)
2014 - Present Member, Pharmacy & Therapeutics Committee, Children's Hospital of Wisconsin
2015 - Present Member, Septicemia Core Team, Children's Hospital of Wisconsin
2017 - Present Analytics of Strategic Plan for Children's Hospital of Wisconsin for US News and World Report for 2017, 2018, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
2017 - Present Invited member, Clinical-Translational Science Review Committee, Children's Wisconsin
2017 - Present Invited Member, Clinical-Translational Science Review Committee - Standing committees to review all Cancer Center pilot grants, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
2017 - Present Analytics of Strategic Plan for Children’s Wisconsin for US News and World Report for 2017, 2018, 2019
2020 - 2022 Streamline scheduling workflow between oncology, interventional radiology, general surgery, Central Venous Access Device Workgroup Meeting
2021 - Present Invited to participate in group of providers to consult on challenging diagnostic cases, Nelson’s Service
04/2022 - Present Member, AYA Working Group- in collaboration with Oncology Program at Froedtert Hospital
09/2022 - Present Member, System Mortality Review Team
11/2023 - Present Culture Ambassador, MACC Fund Center Shared Culture Initiative
2024 - Present Hodgkin Lymphoma National Pediatric Hematology Oncology Advisory Board


MCW TEACHING ACTIVITIES:
Resident and Fellow Education
2013 - Present Ongoing Lectures to Residents and Fellows
2013 - Present Ongoing Didactic Sessions for Residents and Fellows: Lymphoma and lymphadenopathy
2013 - Present Ongoing Didactic Sessions for Residents and Fellows: Hodgkin and Non-Hodgkin lymphoma
2013 - Present Ongoing Didactic Sessions for Residents and Fellows: Controlling Severe Pain In Hospitalized Children
2013 - Present Ongoing Didactic Sessions for Residents and Fellows:E&M Coding in Pediatric Oncology.


EXTRAMURAL TEACHING:
Medical Student Education
2007 University of Minnesota Medical School, Group Instructor, Blood Course
2013 Dallas TX, Common Symptoms and Intern Calls in Oncology - Preparation for Internship, Medical Student Elective
2020 - Present The Mednet. Recruited as nationally recognized expert in pediatric Hodgkin and Non-Hodgkin Lymphoma and Leukemia to answer questions and improve knowledge sharing between physicians to improve patient care

Graduate Student Education
1996 - 2000 Mayo Graduate School, Dept. of Immunology, Immunology Tutor

Resident and Fellow Education
1996 - 2000 Mayo Graduate School, Dept of Immunology, Immunology Tutor
2004 Developed comprehensive study-guide for the Pediatric Licensure Examination based on guidelines from the American Academy of Pediatrics and the American Board of Pediatrics
2007 University of Minnesota Medical School, Tutor, Blood Course
2008 - 2013 University of Texas Southwestern, Ongoing Didactic Sessions for Residents and Fellows: Approach to Reading a Peripheral Blood Smear
2008 - 2013 University of Texas Southwestern, Ongoing Didactic Sessions for Residents and Fellows: Supportive Care in Pediatric Oncology
2008 - 2013 University of Texas Southwestern, Ongoing Didactic Sessions for Residents and Fellows: Introduction to Chemotherapy, Immunotherapy and Immunosuppression
2008 - 2013 University of Texas Southwestern, Ongoing Didactic Sessions for Residents and Fellows: Emergencies in Pediatric Oncology
2008 - 2013 UTSW, Didactic Session for Residents and Fellows: Pain Management in Oncology Patients
2008 - 2013 University of Texas Southwestern, Ongoing Didactic Sessions for Residents and Fellows: Anatomic Approach to Bone Marrow Biopsies
2008 - 2013 University of Texas Southwestern, Ongoing Didactic Sessions for Residents and Fellows: E&M Coding in Pediatric Oncology
2008 - 2013 University of Texas Southwestern, Ongoing and Didactic Sessions for Residents and Fellows: Hodgkin and Non-Hodgkin Lymphoma in Pediatric Oncology.
2010 - 2011 University of Texas Southwestern, Pediatric Residency Advocacy Project Mentor
2011 - 2013 University of Texas Southwestern, Pediatric Residency Mentor (oversee academic progress of six residents during training)
2011 - 2013 University of Texas Southwestern, Pediatric Senior Resident Morning Report (small group case discussion with faculty)

Continuing Medical Education
04/2009 41st Kenneth C. Haltalin Pediatrics for the Practitioner Annual Seminar, Practical and Ethical Dilemmas in Cord Banking
09/2009 The Southwest Center for Pediatric Environmental Health and Lake Country AHEC Conference on Children's Environmental Health, Paris, TX, Pediatric Cancer - An Overview
11/2011 Children's Medical Center in conjunction with UTSW Department of Pediatrics, Dallas, TX, Practical Pediatric Hematology-Oncology 2011: Lymphadenopathy and Lymphoma
11/2013 Children's Hospital of Wisconsin, Hodgkin Lymphoma in children. Oncology nursing lecture series lead by the leukemia and lymphoma group
03/2014 Children's Hospital of Wisconsin, Anaplastic Large Cell Lymphoma. Oncology nursing lecture series lead by the leukemia and lymphoma group
05/2014 Children's Hospital of Wisconsin, Pediatric Hodgkin lymphoma. Oncology nursing education series
05/2014 Children's Hospital of Wisconsin, Emergencies caused by lymphoma: Oncology nursing education series
07/2015 Children's Hospital of Wisconsin, Controlling Severe Pain In Hospitalized Children: Didactic session for recently hired oncology nurses
07/2015 Children's Hospital of Wisconsin, Pediatric Hodgkin and non-Hodgkin lymphoma: Didactic session for recently hired oncology nurses
07/2015 Children's Hospital of Wisconsin, Emergencies in Oncology: Didactic session for recently hired oncology nurses.

Community/Lay Public
1999 - 2001 Individual English Composition Tutor
1999 - 2001 Rochester Public Library, Homework Assistance Study Table
2011 - 2013 West Mesquite High School, Mentor for GT Mentorship Program
2018 - 2019 Mentor for Elements of Health and Medical Insight Student
2019 - 2020 Facilitated discussion on the development of an international clinical trial for relapsed pediatric Hodgkin lymphoma for Student-Centered Pipeline to Advance Research in Cancer Careers (SPARCC) program
2019 - Present Student Centered Pipeline to Advance Research in Cancer Careers (SPARCC) program. Annual didactic sessions and facilitated discussions on the development of an international clinical trial for relapsed pediatric Hodgkin Lymphoma.
2019 - Present Student-Centered Pipeline to Advance Research in Cancer Careers (SPARCC) program. Annual didactic sessions and Facilitated discussions on the development of an international clinical trial for relapsed pediatric Hodgkin lymphoma
2023 I hosted a college student apprentice (Reshi Mereddy) multiple clinic days over the summer
2023 In collaboration with the Student-Centered Pipeline to Advance Research in Cancer Careers (SPARCC) program I hosted multiple student research apprentices in my leukemia and lymphoma clinic over the summer
2023 In collaboration with The Office of Student Inclusion and Diversity at Marquette University High School, I hosted an Apprenticeship in Medicine (AIM) participant (Vuk Jovanovic) within my clinic over the summer
2023 I hosted a college student apprentice (Reshi Mereddy) multiple clinic days over the summer.
2023 In collaboration with the Student Centered Pipeline to Advance Research in Cancer Careers (SPARCC) program I hosted multiple student research apprentices in my leukemia and lymphoma clinic over the summer
2024 - 2025 INSIGHT: Elements of Health & Medicine Program, Mentor for high school student
2024 - 2025 Mentor for high school student through INSIGHT: Elements of Health & Medicine program, Pewaukee, WI
2024 - Present Children's Wisconsin/Medical College of Wisconsin, Pridefest Volunteer
- 2024 Children's Wisconsin/Medical College of Wisconsin, Pridefest Volunteer


MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
2013 - 2014 Aaron Domak, Clinical Apprenticeship Course Preceptor: Mentor, Medical College of Wisconsin
2014 - Present Ashley Quinn, Advisor for medical students in the Clinical Pathways in Quality Improvement and Patient Safety, Medical College of Wisconsin
2014 - Present Victor Redmon, Advisor for medical students in the Clinical Pathways in Quality Improvement and Patient Safety, Medical College of Wisconsin
2014 - 2015, Advisor, for medical student Hemal Patel, Clinical Advising Program, Medical College of Wisconsin
2014 - 2015 Alexandra Lynch, Clinical Apprenticeship Course Preceptor: Mentor, Medical College of Wisconsin
2015 - Present Rachael Henning, Advisor for medical students in the Clinical Pathways in Quality Improvement and Patient Safety, Medical College of Wisconsin
2015 - 2016 Sarah Kelm, Present Clinical Apprenticeship Course Preceptor: Mentor, Medical College of Wisconsin

Clinical/Research Fellows
2013 - 2016 Nathan Schloemer, Mentor - Scholarly Activities Oversight, Medical College of Wisconsin
2014 - 2015 Emily Olson, Pediatric Hematology/Oncology Fellow, Medical College of Wisconsin
2014 - 2016 Melissa Acquazzino, Pediatric Hematology/Oncology Fellow, Medical College of Wisconsin
2016 - 2019 Nikki Sing, Pediatric Cardiology Fellow, Medical College of Wisconsin
2020 - 2022 Leonid Melnikov, Pediatric Hematology/Oncology Fellow, Medical College of Wisconsin
2021 - 2023 Nicole Liberio, Pediatric Hematology/Oncology Fellow, Medical College of Wisconsin
2021 - 2024 Alejandra Escobar Vasco, Pediatric Hematology/Oncology Fellow, Medical College of Wisconsin

Residents
2015 - 2018 Lindsay Hoogenboom, MD, Advisor, Medical College of Wisconsin
2015 - 2016 Michol Holloway, Kathryn Krauss, Jessica Lake, Brilliant Nimmer, Elizabeth Kurowski., Mentor for resident quality improvement project: Improving Resident Preparedness and Comfort in the HOT Unit., Medical College of Wisconsin
2023 - Present Rebecca Volmy, MD, Advisor to Pediatric Resident, Medical College of Wisconsin


EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Residents
2010 - 2011, Pediatric Residency Advocacy Project Mentor, University of Texas, Southwestern Medical Center, Dallas
2011 - 2013, Mentor, Pediatric Residency Program, University of Texas, Southwestern Medical Center, Dallas
2023 - Present Rebecca Volmy, MD, Advisor to Pediatric Resident, The Medical College of Wisconsin

Faculty
2020 - Present Christine Moore Smith, MD Associate Professor, Vanderbilt, Interest in Hodgkin lymphoma, non-Hodgkin lymphoma, quality improvement. Have incorporated her into the COG Hodgkin lymphoma committee, provide individual mentorship
2021 - Present Charles Philips, MD. Assistant Professor, CHOP, interest in informatics and non-Hodgkin lymphoma, non-Hodgkin Lymphoma, have incorporated him into COG NHL committee, EPIC Pediatric Oncology Steering Board
2022 - Present Jenny Belsky, DO. Dr. Assistant Professor, Lead of the Pediatric Lymphoma Team at Riley Hospital for Children, Mentorship on program development, clinical research, the development of international clinical trial in pediatric Hodgkin lymphoma, and am her referee for K08 Award grant


PROGRAMMATIC DEVELOPMENTS:
Educational Programs
Resident
2010 - 2013 Developed and implemented comprehensive inpatient and outpatient education program for pediatric residents on the hematology and oncology service. Included recurring didactic sessions, teaching file
2015 - Present Developed and implement comprehensive inpatient education program for pediatric residents on hematology, oncology and bone marrow transplant


Clinical Programs
2013 Developed a comprehensive plan to improve efficiency and accuracy in documentation in EPIC that complied with provider E&M billing and coding and hospital APR-DRG based billing.
2023 - Present Member, Langerhans Cell Histiocytosis (LCH) Working Group, North American Consortium for Histiocytosis (NACHO)


COMMUNITY SERVICE ACTIVITIES:
1999 - 2001 Individual English Composition Tutor
1999 - 2001 Rochester Public Library, Homework Assistance Study Table
2011 - 2013 West Mesquite High School, Mentor for GT Mentorship Program
2018 - 2019 Mentor for Megan Stoffield, Elements of Health and Medicine Insight course, Pewaukee, WI
2019 - 2020 Mentor for Jayden Schultz, Elements of Health and Medicine Insight course, Pewaukee, WI
2019 - Present Centered Pipeline to Advance Research in Cancer Careers (SPARCC) program. Annual didactic sessions and Facilitated discussions on the development of an international clinical trial for relapsed pediatric Hodgkin lymphoma
2023 - Present Volunteer, Guest House, Milwaukee, WI


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Murray P. Pitt B. Webb RC. Ramipril prevents hypersensitivity to phenylephrine in aorta from streptozotocin-induced diabetic rats. Diabetologia. 37(7):664-70, 1994 Jul.
2. Miller DJ, Njenga MK, Murray PD, Leibowitz J, Rodriguez M. A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system inflammation and increases virus expression after Theiler's virus-induced demyelination. International Immunology 1996;8(1):131-41.
3. Rodriguez M, Rivera-Quinones C, Murray PD, Njenga MK, Wettstein PJ, Mak T. The role of CD4+ and CD8+ T cells in demyelinating disease following Theiler's virus infection: a model for multiple sclerosis. Journal of Neurovirology 1997;3(Suppl 1):S43-S45
4. Lin X, Pease LR, Murray PD, Rodriguez M. Theiler's virus infection of genetically susceptible mice induces central nervous system-infiltrating CTLs with no apparent viral or major myelin antigenic specificity. Journal of Immunology 1998;160(11):5661-8.
5. Murray PD, Pavelko KD, Leibowitz J, Lin X, Rodriguez M. CD4(+) and CD8(+) T cells make discrete contributions to demyelination and neurologic disease in a viral model of multiple sclerosis. Journal of Virology 1998;72(9):7320-9.
6. Murray PD, McGavern DB, Lin X, Njenga MK, Leibowitz J, Pease LR, Rodriguez M. Perforin-dependent neurologic injury in a viral model of multiple sclerosis. Journal of Neuroscience 1998;18(18):7306-14.
7. Murray PD, Njenga MK, McGavern DB, Lin X, Drescher KM, Rodriguez M. Absence of spontaneous central nervous system remyelination in Class II-deficient mice infected with Theiler's Virus. Journal of Neuropathology & Experimental Neurology 1999;58(1):78-91.
8. Drescher KM, Murray PD, David CS, Pease LP, Rodriguez M. CNS cell populations are protected from virus-induced pathology by distinct arms of the immune system. Brain Pathology 1999;9:21-31.
9. McGavern DB, Murray PD, Rodriguez M. Quantitation of spinal cord demyelination, remyelination, atrophy, and axonal loss in a model of progressive neurologic injury. Journal of Neuroscience Research 1999 58:492-504.
10. McGavern DB, Murray PD, Rivera-Quinones C, Schmelzer JD, Low PA, Rodriguez M. Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 2000 123:519-531.
11. Drescher KM, Murray PD, David CS, Lin X, Carlino JA, and Rodriguez M. TGF2 reduces demyelination, limits virus antigen expression, and enhances apoptosis in a viral model of multiple sclerosis. Journal of Immunology 2000 164(6): 3207 - 3213
12. Murray PD, Wei T, Krivacic K, Chernosky A, and Rodriguez M, and Ransohoff RM. Bi-Phasic and regionally-restricted chemokine expression in the central nervous system in a Viral Model of Multiple Sclerosis. Journal of Neurovirology 2000(6) Suppl 1 S44-S52
13. Murray PD, Drescher KM, Leibowitz J, and Rodriguez M. Spontaneous oligodendrocyte-mediated remyelination is associated with improved neurologic function in a viral model of multiple sclerosis. Brain. 2001. 124(Pt 7):1403-16.
14. Murray PD, McGavern DB, Pease LR, Rodriguez M. Cellular sources and targets of IFN-mediated protection against viral demyelination and neurological deficits. European Journal of Immunology. 2002. 32:606-615.
15. Sica G, Harker-Murray PD, Montori VM, Smith SA, for the EVIDENS group. Adherence of Published Diabetes Mellitus Practice Guidelines to Methodological Standards of Guideline Development. Endocrinology and Metabolism Clinics of North America 2002. 31:819-828.
16. Crow SS, Sullivan VV, Aysola AE, Key NS, Harker-Murray PD, Foker JE, Steiner ME.Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg. 2007 Apr;83(4):1547-9.
17. Harker-Murray PD, Lee AB, Ferrieri P, Schleiss M, Tolar J. *Contributed equally. Bacterial meningitis from Rothia mucilaginosa in patients with malignancy or undergoing. hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2008 Mar;50(3):673-6.
18. Harker-Murray PD, Avis J Thomas, MS, Xianghua Luo, PhD, Michael R Verneris, MD, Kathryn E Dusenbery, MD, Margaret L MacMillan, MD, Jakub Tolar, MD, PhD, K. Scott Baker, MD, MS, John E Wagner, MD and Paul J Orchard, MD. Allogenic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System. Biol Blood Marrow Transplant 2008; 14(6): 685-692.
19. Hippen KL, Harker-Murray PD., Porter SB et al Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood. 2008;112:2847-2857
20. Twombley K, Pokala H, Ardura MI, Harker-Murray P, Johnson-Welch SF, Weinberg A, Seikaly M. Intraventricular Rituximab and Systemic Chemotherapy for Treatment of CNS PTLD after Kidney Transplantation Pediatr Transplant. 2012: 16: E201–E20
21. Amy C. Fowler, David Leonard, Tamra Slone, Christian Tellinghuisen, Paul Harker-Murray, Naomi Winick. Average Absolute Neutrophil Count During Maintenance Chemotherapy in Latino versus non-Latino Caucasian Patients with Childhood Acute Lymphoblastic Leukemia (Submitted)
22. Chris Fraser, Patrick Brown, Gail Megason, Hyo Seop Ahn, Bin Cho, Ivan Kirov, Lawrence Frankel, Richard Aplenc, Debra Bensen-Kennedy, Mihaela Munteanu, Jennifer Weaver, Paul Harker-Murray. Open Label Bendamustine for Pediatric Patients With Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes (In Press) J Pediatri Hematol Oncol. 2014 May; 36(4):e212-8
23. Harker-Murray P, Drachtman R, Hodgson D, Chauvenet A, Kelly K, Cole P, Stratification Treatment Intensity in Relapsed Pediatric Hodgkin Lymphoma, Pediatric Blood Cancer. 2013. Epub Journal of Pediatric Blood Cancer 8 Nov. 2013, DOI:10.1002/pbc.24851.
24. Erker C, Harker-Murray P, Burke M.,Emerging Immunotherapy in Pediatric Lymphoma, Future Oncol. 2016 Jan;12(2):257-70
25. Erker C, Harker-Murray P, Talano J., Usual and Unusual Manifestations of Familial Hemophagocytic Lymphohistiocytosis and Langerhans Cell Histiocytosis, Pediatric Clinics of North America 2017 Feb; 64 (1): 91–109
26. Erker C, Huppler A, Walsh T, McCormick M, Southwood J, and Harker-Murray P.,Management of Invasive Conidiobolus Infection During Therapy for Acute Lymphoblastic Leukemia, J Pediatr Hematol Oncol. 2017
27. Esbenshade AJ, Pierson CR, Thompson AL, Reed D, Gupta A, Levy A, Kahalley LS, Harker-Murray P, Schore R, Muscal JA, Embry L, Maloney K, Horton T, Zweidler-Mckay P, Dhall G., Long-term evidence that a pediatric oncology mentorship program for young investigators is feasible and beneficial in the cooperative group setting: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 Mar;65(3).
28. Adam J. Esbenshade, Lisa S. Kahalley, Reto Baertschiger, Roshni Dasgupta, Kelly C. Goldsmith, Paul C. Nathan, Paul Harker-Murray, Carrie L. Kitko, Edward Anders Kolb, Erin S. Murphy, Jodi A. Muscal, Christopher R. Pierson, Damon Reed, Reuven Schore, Yoram Unguru, Rajkumar Venkatramani, Birte Wistinghausen, Girish Dhall, Mentors’ perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children’s Oncology Group, Pediatr Blood Cancer. 2019;e27920. https://doi.org/ 10.1002/pbc.27920
29. Jing Qi; Sachin S. Kumbhar, MD; Paul D. Harker-Murray, MD; Richard L. Tower, MD; Yonggang Lu, PhD; Nghia (Jack) N. Vo, MD. Clinical utilization of PET/MRI in pediatric patients with lymphoma: A single center experience. Submitted to Cancer Imaging
30. Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia 2021 Oct;35(10):2994-2997
31. Paul Harker-Murray, MD, PhD1; Christine Mauz-Körholz, MD; Thierry Leblanc, MD; Maurizio Mascarin, MD; Gérard Michel, MD; Stacy Cooper, MD; Auke Beishuizen, MD, PhD; Kasey J. Leger, MD, MSc; Loredana Amoroso, MD; Salvatore Buffardi, MD; Charlotte Rigaud, MD; Markus Puhlmann; Stephen Francis, MSc; Mariana Sacchi, MD; Peter D. Cole, MD; Richard A. Drachtman, MD; Kara M. Kelly, MD; Stephen Daw, MD. Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin for Children, Adolescents, and Young with Standard-Risk Relapsed or Refractory Hodgkin Lymphoma (Submitted) 2021
32. Mentors’ perspectives on the successes and challenges of mentoring in the COG Young Investigator mentorship program: A report from the Children’s Oncology Group Adam J. Esbenshade, Lisa S. Kahalley, Reto Baertschiger, Roshni Dasgupta, Kelly C. Goldsmith, Paul C. Nathan, Paul Harker-Murray, Carrie L. Kitko, Edward Anders Kolb, Erin S. Murphy, Jodi A. Muscal, Christopher R. Pierson, Damon Reed, Reuven Schore, Yoram Unguru, Rajkumar Venkatramani, Birte Wistinghausen, Girish Dhall. Pediatr Blood Cancer. 2019;e27920. https://doi.org/ 10.1002/pbc.27920
33. Jing Qi; Sachin S. Kumbhar, MD; Paul D. Harker-Murray, MD; Richard L. Tower, MD; Yonggang Lu, PhD; Nghia (Jack) N. Vo, MD. Clinical utilization of PET/MRI in pediatric patients with lymphoma: A single center experience. (Submitted to Cancer Imaging) 2021
34. Paul Harker-Murray, MD, PhD, Lauren Pommert, MD, MS, Matthew J Barth, MD. Novel Therapies Potentially Available for Pediatric B-NHL. Journal of the National Comprehensive Cancer Network Journal of the National Comprehensive Cancer Network (JNCCN) 18(8):1125-1134 2021
35. Jing Qi, MD; Pooja D. Thakrar; Paul D. Harker-Murray, MD; Richard L. Tower, MD; Nghia (Jack) N. Vo, MD; Sachin S. Kumbhar, MD. Preliminary experience with 30-minute PET/MRI for evaluation of pediatric lymphoma (Submitted to Pediatric Radiology) 2021
36. David T. Teachey MD, Meenakshi Devidas PhD, Brent L Wood MD, PhD, Zhiguo Chen MS, Robert J Hayashi MD, Michelle L. Hermiston, MD PhD, Robert D Annett PhD, J. Hunter Archer BS, Barbara L Asselin MD, Keith J August MD MS, Steve Y Cho MD, Kimberly P. Dunsmore MD, Brian T. Fisher DO MSCE, Jason L. Freedman MD, Paul J. Galardy MD, Paul Harker-Murray MD PhD, Terzah M Horton MD PhD, Alok I Jaju MD, Allison Lam BCPS, Yoav H. Messinger MD, Rodney R. Miles MD PhD, Maki Okada RN, Samir I Patel MD, Eric S. Schafer MD MHS, Tal Schechter-Finkelstein MD, Kristin A. Shimano MD, Neelam Singh PhD, Amii C. Steele PhD, Maria L. Sulis MD, Sarah L Vargas PhD, Stuart S. Winter MD, Charlotte Wood CCRP, Patrick Zweider-McKay MD PhD, Catherine M. Bollard MD MBChB, Mignon L. Loh MD, Stephen P. Hunger MD and Elizabeth A. Raetz MD Children’s Oncology Group Trial AALL: A Phase Clinical Trial Testing Bortezomib in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia and Lymphoma (Submitted) 2021
37. Olivia M.T. Davies, MD; John M. Astle, MD, PhD; Paul D. Harker-Murray, MD, PhD; Karolyn A. Wanat, MD; Valerie M. Carlberg, MD. Cutaneous Presentation of ALK+ Anaplastic Large Cell Lymphoma in a 12-year-old Male with Regional Nodal Involvement (Submitted to Pediatric Dermatology, 2021)
38. Amanda Scheuerman DO; Paul Harker-Murray MD, PhD; Lauren Pommert MD MS. Posterior Reversible Encephalopathy Syndrome in the Setting of Asparaginase-Associated Pancreatitis in Two Pediatric Patients with Acute Leukemia (J Pediatr Hematol Oncol.) 2021 • This is a mentored publication
39. Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma. Leukemia 2021 Oct;35(10):2994-2997
40. Amanda Scheuerman DO; Paul Harker-Murray MD, PhD; Lauren Pommert MD MS. Posterior Reversible Encephalopathy Syndrome in the Setting of Asparaginase-Associated Pancreatitis in Two Pediatric Patients with Acute Leukemia (J Pediatr Hematol Oncol 2022;44:e709–e712) • This is a mentored publication
41. Paul Harker-Murray, MD, PhD1; Christine Mauz-Körholz, MD; Thierry Leblanc, MD; Maurizio Mascarin, MD; Gérard Michel, MD; Stacy Cooper, MD; Auke Beishuizen, MD, PhD; Kasey J. Leger, MD, MSc; Loredana Amoroso, MD; Salvatore Buffardi, MD; Charlotte Rigaud, MD; Markus Puhlmann; Stephen Francis, MSc; Mariana Sacchi, MD; Peter D. Cole, MD; Richard A. Drachtman, MD; Kara M. Kelly, MD; Stephen Daw, MD. Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin for Children, Adolescents, and Young with Standard-Risk Relapsed or Refractory Hodgkin Lymphoma (Submitted)
42. Jing Qi, MD; Pooja D. Thakrar; Paul D. Harker-Murray, MD; Richard L. Tower, MD; Nghia (Jack) N. Vo, MD; Sachin S. Kumbhar, MD. Preliminary experience with 30-minute PET/MRI for evaluation of pediatric lymphoma (Submitted to Pediatric Radiology)
43. David T. Teachey MD, Meenakshi Devidas PhD, Brent L Wood MD, PhD, Zhiguo Chen MS, Robert J Hayashi MD, Michelle L. Hermiston, MD PhD, Robert D Annett PhD, J. Hunter Archer BS, Barbara L Asselin MD, Keith J August MD MS, Steve Y Cho MD, Kimberly P. Dunsmore MD, Brian T. Fisher DO MSCE, Jason L. Freedman MD, Paul J. Galardy MD, Paul Harker-Murray MD PhD, Terzah M Horton MD PhD, Alok I Jaju MD, Allison Lam BCPS, Yoav H. Messinger MD, Rodney R. Miles MD PhD, Maki Okada RN, Samir I Patel MD, Eric S. Schafer MD MHS, Tal Schechter-Finkelstein MD, Kristin A. Shimano MD, Neelam Singh PhD, Amii C. Steele PhD, Maria L. Sulis MD, Sarah L Vargas PhD, Stuart S. Winter MD, Charlotte Wood CCRP, Patrick Zweider-McKay MD PhD, Catherine M. Bollard MD MBChB, Mignon L. Loh MD, Stephen P. Hunger MD and Elizabeth A. Raetz MD Children’s Oncology Group Trial AALL: A Phase Clinical Trial Testing Bortezomib in Newly Diagnosed T-cell Acute Lymphoblastic Leukemia and Lymphoma (Journal of Clinical Oncology, In Press)
44. Olivia M.T. Davies, MD; John M. Astle, MD, PhD; Paul D. Harker-Murray, MD, PhD; Karolyn A. Wanat, MD; Valerie M. Carlberg, MD. A 12-year-old male with localized, pink, tender papules (Pediatric Dermatology Vol 40, No 2, March/April 2023, Pages 367-368)
45. Scheuermann, Amanda DO; Moskop, Amy MD; Hopp, Amanda MD; Bone, Kathleen PhD; Drendel, Holli M. PhD; Talano, Julie MD; Harker-Murray, Paul MD, PhD; Astle, John MD, PhD Pediatric Donor Cell Acute Lymphoblastic Leukemia Following Bone Marrow Transplant for GATA2 Mutation. Journal of Pediatric Hematology and Oncology (March 2022)
46. Amanda L. Scheuermann; Paul D. Harker Murray; Scott K. Van Why; Amanda M. Hopp; Kara E. Young; John J. Dillon; Christian Hanna. Nephrogenic Systemic Fibrosis with a Group II Gadolinium-Based Contrast Agent in a Pediatric Patient with Leukemia and Acute Kidney Injury (Accepted in Pediatric Nephrology, 2021) • This is a mentored publication
47. Lauren J. Miller, MJ; Vasiliki Leventaki, MD, Paul D. Harker-Murray, MD, PhD; Holli M. Drendel, PhD; Kathleen M. Bone, PhD A complex KMT2A:AFF3 fusion resulting from a three-way chromosomal rearrangement in pediatric B lymphoblastic leukemia (Cancer Genetics, In Press, 2021) • This is a mentored publication
48. Paul Harker-Murray, MD, PhD1; Christine Mauz-Körholz, MD; Thierry Leblanc, MD; Maurizio Mascarin, MD; Gérard Michel, MD; Stacy Cooper, MD; Auke Beishuizen, MD, PhD; Kasey J. Leger, MD, MSc; Loredana Amoroso, MD; Salvatore Buffardi, MD; Charlotte Rigaud, MD; Markus Puhlmann; Stephen Francis, MSc; Mariana Sacchi, MD; Peter D. Cole, MD; Richard A. Drachtman, MD; Kara M. Kelly, MD; Stephen Daw, MD. Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin for Children, Adolescents, and Young with Standard-Risk Relapsed or Refractory Hodgkin Lymphoma (Blood. 2023 Apr 27;141(17):2075-2084)
49. Christopher Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, , Rebecca Deyell, Jamie Flerlage, Anna Franklin, Jennifer Krajewski, Kasey Leger, Lianna Marks, Robin Norris, Martha Pacheco, Faye Willen, Adam Yan, Paul Harker-Murray, Lisa Giulino-Roth. Brentuximab Vedotin Following Autologous Transplantation in Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma (Blood Adv 2023 Mar 10, online ahead of print)
50. Jennifer A. Belsky DO, MS a b, Jamie Shoag MD, MPH c, Paul D. Harker-Murray MD, PhD d, Justine M. Kahn MD, MS. Advances in Pediatric Hodgkin Lymphoma with an Eye on Disparities and Vulnerable Populations. Advances in Oncology Volume 3, Issue 1, May 2023, Pages 67-76
51. Radiotherapy Use in Refractory and Relapsed Pediatric Hodgkin Lymphoma: A Report from the Children's Oncology Group (International Journal of Radiation Oncology, Biology, Physics, In Press)
52. Sharon M. Castellino, Lisa Giulino-Roth, Paul Harker-Murray, Justine Kahn, Christopher Forlenza, Steve Cho, Brad Hoppe, Susan K. Parsons, Kara M. Kelly on behalf of the COG Hodgkin Lymphoma Committee. Children’s Oncology Group’s 2023 Blueprint for Research: Hodgkin Lymphoma. Pediatr Blood Cancer. 2023;e30580.
53. Sarah Alexander, Paul Harker-Murray, Robert J. Hayashi, Editorial: Non-cellular immunotherapies in pediatric malignancies. Front. Immunol, Sec. Cancer Immunity and Immunotherapy. Vol 15, 20 February 2024.
54. Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas S, Winter SS, Wood C, Zweider-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE, MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trail AALL1231. Blood. 2024. Mar 8: blood2023021184...Online ahead of print.
55. Sarah Alexander, Paul Harker-Murray, Robert J. Hayashi, Editorial: Non-cellular immunotherapies in pediatric malignancies. Front. Immunol., Sec. Cancer Immunity and Immunotherapy. Vol 15, 20 February 2024.
56. Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas S, Winter SS, Wood C, Zweider-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE MRD at the End of Induction and EFS in T-cell Lymphoblastic Lymphoma: Children's Oncology Group Trial AALL1231. .Blood. 2024 Mar 8: blood.2023021184.. Online ahead of print.
57. Stephen Daw, Peter D. Cole, Bradford S. Hoppe, David Hodgson, Auke Beishuizen, Nathalie Garnier, Salvatore Buffardi, Maurizio Mascarin, Andrej Lissat, Christine Mauz-Körholz, Jennifer Krajewski, Alev Akyol, Russell Crowe, Bailey Anderson, Yan Xu, Richard A. Drachtman, Kara M. Kelly, Thierry Leblanc, Paul Harker-Murray. Transplant-free relapsed Hodgkin lymphoma with nivolumab, brentuximab vedotin, and radiotherapy. JAMA Oncology, 2024, In Press

Abstracts
1. Murray PD, Lin X, Njenga MK, Leibowitz J, Pease LR, Rodriguez M. Perforin and Fas-mediated cytotoxic effector function in the development of demyelination and neurologic deficits in a viral model of multiple sclerosis. Platform Presentation: American Association of Neuropathologists Annual Meeting (June 1998), and Poster Presentation: 1998 Southern Minnesota Chapter of the Society for Neuroscience
2. Murray PD, Pavelko K, Leibowitz J, Pease LR, Rodriguez M. CD4+ and CD8+ T cells make discrete contributions to demyelination and neurologic disease in a viral model of multiple sclerosis. Poster Presentation: 1999 Southern Minnesota Chapter of the Society for Neuroscience
3. Murray PD, Drescher KM, Leibowitz J, and Rodriguez M. Extensive Myelin Repair in a Viral Model of Multiple Sclerosis. Poster Presentation: 1999 Experimental Biology (FASEB) April 1999, and Poster Presentation: 1999 Southern Minnesota Chapter of the Society for Neuroscience.
4. Murray PD, McGavern DB, Pease LR, Rodriguez M. Independent production of IFN by CD4 + and CD8+ T cells is required for resistance to viral persistence demyelination, and neurologic disease following infection with Theiler’s virus. Poster Presentation: June 1999, Gordon Research Conference on Neurovirology
5. Harker-Murray PD, Tolar J Tan Y, MacMillan ML Wagner JE, Orchard PJ. Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Isolated CNS Relapse. Poster Presentation. 2005 Annual Meeting of the American Society of Hematology. Abstract #2745 appears in Blood, Volume 106, issue 11, November 16, 2005
6. Harker-Murray PD, Dayton V, Neglia J, Tolar J Treatment of EBV-associated T cell post-transplant lymphoproliferative disorder with CNS involvement in a pediatric solid-organ transplant patient. 2006 ASCO Annual Meeting, Abstract No 9040.
7. Harker-Murray PD, Verneris MR, Thomas AJ, Luo X, MacMillan ML, Tolar J, Baker KS, Wagner JE, Orchard PJ. Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Relapsed Acute Lymphoblastic Leukemia with and without CNS Involvement. 2006 ASH Annual Meeting.
8. Pokala H, WeinbergA , Harker-Murray PD . The Management of Post-Transplant Lymphoproliferative Disorder Resembling Primary CNS Lymphoma in a Pediatric Renal Transplant Patient. 2010 ASPHO Annual Meeting
9. Gupta P, Harker-Murray PD, Sunitinib treatment of malignant pheochromocytoma in a pediatric patient. 2010 ASPHO Annual Meeting
10. Chris Fraser, Patrick Brown, Gail Megason, Hyo Seop Ahn, Bin Cho, Ivan Kirov, Lawrence Frankel, Richard Aplenc, Debra Bensen-Kennedy, Mihaela Munteanu, Jennifer Weaver, Paul Harker-Murray. Open Label Bendamustine for Pediatric Patients With Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes (2011 ASPHO Annual Meeting)
11. Christopher Henchen, Tiffany Morese, Rebecca Rehborg CCRT, Mary Kirby, Malini Shankar CCRP, Paul Harker Murray. Audit readay all the time: The digital clinical trials office. 2015 Children’s Oncology group Annual Meeting)
12. Lauren Ranallo, MSN, RN, AOCNS, CPHON, Carolyn Herda, BSN, RN, Gina Leonard, BSN, RN, Jody Orluske, BSN, RN, Kelly Pergande, BSN, RN, Paul Harker-Murray, MD, PhD 2016 National Association of Clinical Nurse Specialists Conference
13. Prevention of Central Line Associated Bloodstream Infections using Standard Bundles Varies by Patient Population (submitted to pediatric Academic Society Annual Meeting)
14. Craig Erker, Anna Huppler, Thomas J. Walsh, Neel Bhatt, Paul Harker-Murray. Conidiobolus Infection: Management during Induction Therapy for Acute Lymphoblastic Leukemia. American Society of Pediatric Hematology and Oncology Annual Meeting, 2016, Abstract 744.
15. Ashley Quinn BS1; Lauren Ranallo MSN, RN, AOCNS, CPHON; Alyse Bartczak BSN, RN; Paul Harker-Murray MD, PhD. Reducing CLABSIs in Pediatric Oncology Patients. Platform presentation. American College of Physicians, Wisconsin Chapter, 2016 Annual Meeting
16. Jeanne Braby, MSN, RN, CCRN; Rainer Gedeit, M.D.; Vijendar Karody, M.D.; Paul Harker-Murray, M.D., PhD “Reduction of central line associated bloodstream infections using standard bundles varies by patient population” 16th Annual International Symposium on Congenital Heart Disease St. Petersburg, FL. February 13-16, 2016
17. Jeanne Braby, MSN, RN, CCRN; Rainer Gedeit, M.D.; Vijendar Karody, M.D.; Paul Harker-Murray, M.D., PhD Reduction of Central Line Associated Bloodstream Infections Using Standard Bundles Varies by Patient Population. Children’s Hospital of Wisconsin Pediatric Nursing Conferenc, November 2, 2016. Brookfield, WI
18. Paul D Harker-Murray, William Meyer, Stephen Skapek, Min Kang, Bambang Adiwijaya, Jonathan Fitzgerald, Chrystal U Louis, Daryl Drummond, C Patrick Reynolds5 Plasma Pharmacokinetics of MM-398 (Nal-IRI, Liposomal Irinotecan) in Pediatric Oncology Patients with Recurrent or Refractory Solid Tumors: South Plains Oncology Consortium Study 2012-001. Submitted to the e 48th Annual Congress of the International Society of Paediatric Oncology, October 19-22, 2016, Dublin Ireland
19. Paul Harker-Murray, Richard Drachtman, Kara M Kelly, Mariana Sacchi, Thierry Leblanc, Peter D Cole, Suresh Shelat, Stephen Daw CheckMate 744: Phase 2 Study of Nivolumab Plus Brentuximab Vedotin for Children, Adolescents, and Young Adults With Relapsed/Refractory CD30+ Classical Hodgkin Lymphoma. Submitted to the 14th International Conference on Malignant Lymphoma 2017; Lugano, Switzerland
20. Lauren Pommert, MD, Nathan Schloemer, MD and Paul Harker-Murray, MD, PhD. Primary Extrarenal Wilms tumor of the testis. Submitted to the American Society of Pediatric Hematology and Oncology annual meeting, 2018
21. Paul Harker-Murray, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey Leger, Alberto Garaventa, Laurence Brugieres, Kara Kelly, Peter D. Cole, Richard A. Drachtman, Faith Galderisi, Mariana Sacchi, Ying-Ming Jou, Stephen Daw. Response-Adapted Therapy With Nivolumab, Brentuximab Vedotin and Bendamustine in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma. Oral Presentation. American Society of Hematology Annual Meeting, 2018, Abstract Number 927
22. Paul Harker-Murray, Thierry Leblanc, Maurizio Mascarin, Christine Mauz-Körholz, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugieres, Kara Kelly, Peter D Cole, Richard A Drachtman, Faith Galderisi, Mariana Sacchi, Stephen Francis, Stephen Daw. Nivolumab, Brentuximab Vedotin, and Bendamustine as Response-Adapted Treatment for Relapsed or Refractory Hodgkin Lymphoma in Children, Adolescents and Young Adults: Results from the Standard-Risk Cohort of the Phase 2 Checkmate 744 Study. Submitted to the British Society for Haematology – 59th Annual Meeting
23. Adam J. Esbenshade, Lisa S. Kahalley, Reto Baertschiger, Roshni Dasgupta, Kelly Goldsmith, Paul Nathan, Paul Harker-Murray, Carrie L. Kitko, Andy Kolb, Erin Murphy, Jodi A. Muscal, Christopher Pierson, Damon Reed, Reuven Shore, Yoram Unguru, Raj Venkatramani, Birte Wistinghausen, Girish Dhall Long-term evidence that a pediatric oncology mentorship program for young investigators is beneficial to the mentors in a cooperative group setting: A report from the Children's Oncology Group. Submitted 2019 ASPHO Conference May 1 - 4, 2019, in New Orleans, LA
24. Thierry Leblanc, Paul Harker-Murray, Christine Mauz-Körholz, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugieres, Kara M. Kelly, Peter D. Cole, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Stephen Daw. Nivolumab and brentuximab vedotin-based response-adapted treated for relapsed/refractory classical Hodgkin lymphoma in pediatric and primary refractory patients in Checkmate 744. 24th European Hematology Association (EHA) Annual Meeting; 2019 (Oral Presentation)
25. Kara M. Kelly, Stephen Daw, Christine Mauz-Körholz, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugières, Peter D. Cole, Paul Harker-Murray, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Thierry Leblanc. Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: CheckMate 744 Subgroup Analyses. 15th Annual International Conference on Malignant Lymphoma (ICML), 2019 (Oral Presentation)
26. Kara M. Kelly, Stephen Daw, Christine Mauz-Körholz, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugières, Paul Harker-Murray, Peter D. Cole, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Thierry Leblanc. “Nivolumab and Brentuximab Vedotin-Based, Response-Adapted Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma in Primary Refractory and in Pediatric Patients in CheckMate 744” International Conference on Malignant Lymphoma (ICML), 2019, (Oral presentation)
27. Kara M. Kelly, Stephen Daw, Christine Mauz-Körholz, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugières, Paul Harker-Murray, Peter D. Cole, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Thierry Leblanc. Treatment with Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: CheckMate 744 Subgroup Analyses from study CA209-744; at the Society of Hematologic Oncology - 7th Annual Meeting on Sep 11, 2019 in Houston, TX, United States. The abstract will be an encore from ICML 2019.
28. Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in primary refractory patients (pts) and in pediatric pts with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in the phase 2 CheckMate 744 study Christine Mauz-Körholz, Thierry Leblanc, Paul Harker-Murray, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugières, Kara M. Kelly, Peter D. Cole, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Stephen Daw. JAHRESTAGUNG Jahrestagung DGHO 2019 (2019 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology)
29. Kara M. Kelly, Stephen Daw, Christine Mauz-Körholz, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugières, Paul Harker-Murray, Peter D. Cole, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Thierry Leblanc. Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents, and Young Adults (CAYA) With Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): CheckMate 744 Subgroup Analyses. Society of Hematologic Oncology 2019 annual meeting. Event 4th International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma
30. P. Harker-Murray, Q. Pei, C. Forlenza, R. Drachtman, P. Cole, K. Kelly A New Model for Stratification of Treatment Intensity in Relapsed Pediatric Hodgkin Lymphoma. . Poster presentation: 4th International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma
31. Peter D. Cole, MD; Christine Mauz-Körholz, MD, Maurizio Mascarin, MD; Gérard Michel, MD; Stacy Cooper, MD; Auke Beishuizen, MD, PhD; Kasey J. Leger, MD, MSc; Loredana Amoroso, MD; Salvatore Buffardi, MD; Charlotte Rigaud, MD; Markus Puhlmann; Stephen Francis, MSc; Mariana Sacchi, MD; Richard A. Drachtman, MD; Paul Harker-Murray, MD, PhD; Thierry Leblanc, MD; Stephen Daw, MD; Kara K. Kelly, MD. Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis. American Society of Clinical Oncology Annual Meeting 2020
32. Christine Mauz-Körholz, Thierry Leblanc, Maurizio Mascarin, Gérard Michel, Auke Beishuizen, Stacy Cooper, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Markus Puhlmann, Stephen Francis, Mariana Sacchi, Peter D. Cole, Richard A. Drachtman, Paul Harker-Murray, Kara M. Kelly, Stephen DawResponse-adapted therapy with nivolumab and brentuximab vedotin in children, adolesents and young adutls with standard risk relapsed/refractory classical Hodgkin lymphoma: Checkmate 744. Abstract S224. 25th congress of the European Hematology Association (Oral Presentation)
33. Moskop, AM, Harker-Murray, P, Relapsed Hodgkin Lymphoma Successfully Treated with Targeted Immunotherapy And Chemotherapy, Accepted for poster presentation at the American Society of Pediatric Hematology-Oncology Conference, Fort Worth, TX, 05/2020
34. Moskop, AM, Tower, R, Harker-Murray, P, Residual disease detected by PET/MRI in CNS relapse of Primary Mediastinal B Cell Lymphoma, Accepted for poster presentation at the American Society of Pediatric Hematology-Oncology Conference, Fort Worth, TX, 05/2020
35. Peter D. Cole, MD; Christine Mauz-Körholz, MD, Maurizio Mascarin, MD; Gérard Michel, MD; Stacy Cooper, MD; Auke Beishuizen, MD, PhD; Kasey J. Leger, MD, MSc; Loredana Amoroso, MD; Salvatore Buffardi, MD; Charlotte Rigaud, MD; Markus Puhlmann; Stephen Francis, MSc; Mariana Sacchi, MD; Richard A. Drachtman, MD; Paul Harker-Murray, MD, PhD; Thierry Leblanc, MD; Stephen Daw, MD; Kara K. Kelly, MD. Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis. American Society of Clinical Oncology – 56th Annual Meeting
36. Peter D. Cole, MD; Christine Mauz-Körholz, MD, Maurizio Mascarin, MD; Gérard Michel, MD; Stacy Cooper, MD; Auke Beishuizen, MD, PhD; Kasey J. Leger, MD, MSc; Loredana Amoroso, MD; Salvatore Buffardi, MD; Charlotte Rigaud, MD; Markus Puhlmann; Stephen Francis, MSc; Mariana Sacchi, MD; Richard A. Drachtman, MD; Paul Harker-Murray, MD, PhD; Thierry Leblanc, MD; Stephen Daw, MD; Kara K. Kelly, MD. Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis. Deutsche Gesellschaft fur Hamatologie und Medizinische Onkologie – 2020 (submitted)
37. Peter D. Cole, Christine Mauz-Körholz, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Markus Puhlmann, Stephen Francis, Mariana Sacchi, Richard A. Drachtman, Paul Harker-Murray, Thierry Leblanc, Stephen Daw, Kara M. Kelly. Nivolumab and Brentuximab Vedotin (BV)–Based, Response‐Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study. Eighth Annual Meeting of the Society of Hematologic Oncology (SOHO), 2020
38. Christine Mauz-Körholz, Peter D. Cole, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Markus Puhlmann, Stephen Francis, Mariana Sacchi, Richard A. Drachtman, Paul Harker-Murray, Thierry Leblanc, Stephen Daw, Kara M. Kelly. Nivolumab (nivo) and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis of the R2 cohort of the phase 2 CheckMate 744 study Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (DGHO) 2020
39. Adam J. Esbenshade, Lisa S. Kahalley, Reto Baertschiger, Roshni Dasgupta, Kelly Goldsmith, Paul Nathan, Paul Harker-Murray, Carrie L. Kitko, Andy Kolb, Erin Murphy, Jodi A. Muscal, Christopher Pierson, Damon Reed, Reuven Shore, Yoram Unguru, Raj Venkatramani, Birte Wistinghausen, Girish Dhall Long-term evidence that a pediatric oncology mentorship program for young investigators is beneficial to the mentors in a cooperative group setting: A report from the Children's Oncology Group. Submitted 2019 ASPHO Conference May 1 - 4, 2019, in New Orleans, LA
40. Thierry Leblanc, Paul Harker-Murray, Christine Mauz-Körholz, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugieres, Kara M. Kelly, Peter D. Cole, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Stephen Daw. Nivolumab and brentuximab vedotin-based response-adapted treated for relapsed/refractory classical Hodgkin lymphoma in pediatric and primary refractory patients in Checkmate 744. 24th European Hematology Association (EHA) Annual Meeting; 2019 (Oral Presentation)
41. Kara M. Kelly, Stephen Daw, Christine Mauz-Körholz, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugières, Peter D. Cole, Paul Harker-Murray, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Thierry Leblanc. Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: CheckMate 744 Subgroup Analyses. 15th Annual International Conference on Malignant Lymphoma (ICML), 2019 (Oral Presentation)
42. Kara M. Kelly, Stephen Daw, Christine Mauz-Körholz, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugières, Paul Harker-Murray, Peter D. Cole, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Thierry Leblanc. “Nivolumab and Brentuximab Vedotin-Based, Response-Adapted Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma in Primary Refractory and in Pediatric Patients in CheckMate 744” International Conference on Malignant Lymphoma (ICML), 2019, (Oral presentation)
43. Kara M. Kelly, Stephen Daw, Christine Mauz-Körholz, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugières, Paul Harker-Murray, Peter D. Cole, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Thierry Leblanc. Treatment with Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: CheckMate 744 Subgroup Analyses from study CA209-744; at the Society of Hematologic Oncology - 7th Annual Meeting on Sep 11, 2019 in Houston, TX, United States. The abstract will be an encore from ICML 2019.
44. Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in primary refractory patients (pts) and in pediatric pts with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in the phase 2 CheckMate 744 study Christine Mauz-Körholz, Thierry Leblanc, Paul Harker-Murray, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugières, Kara M. Kelly, Peter D. Cole, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Stephen Daw. JAHRESTAGUNG Jahrestagung DGHO 2019 (2019 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology)
45. Kara M. Kelly, Stephen Daw, Christine Mauz-Körholz, Maurizio Mascarin, Gerard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Alberto Garaventa, Salvatore Buffardi, Laurence Brugières, Paul Harker-Murray, Peter D. Cole, Richard A. Drachtman, Thomas Manley, Stephen Francis, Mariana Sacchi, Thierry Leblanc. Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents, and Young Adults (CAYA) With Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): CheckMate 744 Subgroup Analyses. Society of Hematologic Oncology 2019 annual meeting. Event 4th International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma
46. P. Harker-Murray, Q. Pei, C. Forlenza, R. Drachtman, P. Cole, K. Kelly A New Model for Stratification of Treatment Intensity in Relapsed Pediatric Hodgkin Lymphoma. . Poster presentation: 4th International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma
47. Peter D. Cole, MD; Christine Mauz-Körholz, MD, Maurizio Mascarin, MD; Gérard Michel, MD; Stacy Cooper, MD; Auke Beishuizen, MD, PhD; Kasey J. Leger, MD, MSc; Loredana Amoroso, MD; Salvatore Buffardi, MD; Charlotte Rigaud, MD; Markus Puhlmann; Stephen Francis, MSc; Mariana Sacchi, MD; Richard A. Drachtman, MD; Paul Harker-Murray, MD, PhD; Thierry Leblanc, MD; Stephen Daw, MD; Kara K. Kelly, MD. Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis. American Society of Clinical Oncology Annual Meeting 2020
48. Christine Mauz-Körholz, Thierry Leblanc, Maurizio Mascarin, Gérard Michel, Auke Beishuizen, Stacy Cooper, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Markus Puhlmann, Stephen Francis, Mariana Sacchi, Peter D. Cole, Richard A. Drachtman, Paul Harker-Murray, Kara M. Kelly, Stephen DawResponse-adapted therapy with nivolumab and brentuximab vedotin in children, adolesents and young adutls with standard risk relapsed/refractory classical Hodgkin lymphoma: Checkmate 744. Abstract S224. 25th congress of the European Hematology Association (Oral Presentation)
49. Moskop, AM, Harker-Murray, P, Relapsed Hodgkin Lymphoma Successfully Treated with Targeted Immunotherapy And Chemotherapy, Accepted for poster presentation at the American Society of Pediatric Hematology-Oncology Conference, Fort Worth, TX, 05/2020
50. Moskop, AM, Tower, R, Harker-Murray, P, Residual disease detected by PET/MRI in CNS relapse of Primary Mediastinal B Cell Lymphoma, Accepted for poster presentation at the American Society of Pediatric Hematology-Oncology Conference, Fort Worth, TX, 05/2020
51. Peter D. Cole, MD; Christine Mauz-Körholz, MD, Maurizio Mascarin, MD; Gérard Michel, MD; Stacy Cooper, MD; Auke Beishuizen, MD, PhD; Kasey J. Leger, MD, MSc; Loredana Amoroso, MD; Salvatore Buffardi, MD; Charlotte Rigaud, MD; Markus Puhlmann; Stephen Francis, MSc; Mariana Sacchi, MD; Richard A. Drachtman, MD; Paul Harker-Murray, MD, PhD; Thierry Leblanc, MD; Stephen Daw, MD; Kara K. Kelly, MD. Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis. American Society of Clinical Oncology – 56th Annual Meeting
52. Peter D. Cole, MD; Christine Mauz-Körholz, MD, Maurizio Mascarin, MD; Gérard Michel, MD; Stacy Cooper, MD; Auke Beishuizen, MD, PhD; Kasey J. Leger, MD, MSc; Loredana Amoroso, MD; Salvatore Buffardi, MD; Charlotte Rigaud, MD; Markus Puhlmann; Stephen Francis, MSc; Mariana Sacchi, MD; Richard A. Drachtman, MD; Paul Harker-Murray, MD, PhD; Thierry Leblanc, MD; Stephen Daw, MD; Kara K. Kelly, MD. Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis. Deutsche Gesellschaft fur Hamatologie und Medizinische Onkologie – 2020 (submitted)
53. Peter D. Cole, Christine Mauz-Körholz, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Markus Puhlmann, Stephen Francis, Mariana Sacchi, Richard A. Drachtman, Paul Harker-Murray, Thierry Leblanc, Stephen Daw, Kara M. Kelly. Nivolumab and Brentuximab Vedotin (BV)–Based, Response‐Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study. Eighth Annual Meeting of the Society of Hematologic Oncology (SOHO), 2020
54. Christine Mauz-Körholz, Peter D. Cole, Maurizio Mascarin, Gérard Michel, Stacy Cooper, Auke Beishuizen, Kasey J. Leger, Loredana Amoroso, Salvatore Buffardi, Charlotte Rigaud, Markus Puhlmann, Stephen Francis, Mariana Sacchi, Richard A. Drachtman, Paul Harker-Murray, Thierry Leblanc, Stephen Daw, Kara M. Kelly. Nivolumab (nivo) and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis of the R2 cohort of the phase 2 CheckMate 744 study Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (DGHO) 2020 (Video Presentation)
55. Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Annett R, Asselin B, August K, Cho S, Dunsmore K, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Hermiston M, Horton T, Jaju AI, Lam A, Messinger YH, Miles RR, Okada N, Patel SI, Rao KW, Schafer ES, Schechter-Finkelstein T, Shimano KA, Singh N, Steele AC, Sulis ML, Vargas SL, Winter S, Wood C, Zweidler-McKay PA, Bollard CM, Loh ML, Hunger SP, and Raetz EA*. Children’s Oncology Group (COG) Trial AALL1231: Cranial Radiation Can Be Eliminated in Most Children with T-cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-cell Lymphoblastic Lymphoma (T-LL). American Society of Hematology 2020 Annual Meeting.
56. Jessica Hochberg, Stan Goldman, Matthew Barth, Qiuhu Shi, Liana Klejmont, Lauren Harrison,Jackie Basso, Yaya Chu, Humayun Islam, Perry Gerard, Javier Oesterheld, Kenneth Heym, Ivan Kirov, Richard Drachtman, Paul Harker-Murray, Sherrie Perkins, Rodney Miles, Bruce Shiramizu, and Mitchell Cairo. Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with de Novo Good Risk Mature B-cell Lymphoma. American Society of Hematology 2020 Annual Meeting.
57. Miller, LJ; Scheuermann, A; Harker-Murray, P. Glutamine Supplementation and the Prevention of Mucositis and Infection During Chemotherapy: A quality improvement project.
58. Paul Harker-Murray, MD, PhD, Brent L Wood, MD, PhD, Meenakshi Devidas, PhD, Zhinguo Chen, MS4, Tal Schecter-Finkelstein, MD, Robert J Hayashi, MD, Keith J August, MD, MS, Kimberly P Dunsmore, MD, Michelle L Hermiston, MD, PhD, Terzah Horton, MD, PhD, Yoav H Messinger, MD, Eric S Schafer, MD, MHS, Maria L Sulis, MD, Sarah L Vargas, PhD, Stuart S Winter, MD, Charlotte Wood, CCRP, Catherine M Bollard, MD, MBChB, Mignon L Loh, MD, Steve P Hunger, MD, Elizabeth A Raetz, MD, David T Teachey, MD, Intensification of chemotherapy using a modified BFM backbone for children, adolescents and young adults with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) identifies highly chemorefractory patients who benefit from allogeneic hematopoietic stem cell transplantation, American Society of Hematology 2021 Annual Meeting (Abstract 3487)
59. Christopher Forleza, Jaclyn Rosensweig, Audrey Mauguen, Paul Harker-Murray, Lisa Giulinio-Roth. Brentuximab Vedotin as Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis. Submitted to the American Society of Hematology 2021 Annual Meeting (Abstract 2465)
60. Raymond Mailhot Vega, Paul Harker-Murray, Christopher Forlenza, Peter Cole, Kara Kelly, Sarah Milgrom, Rahul Parikh, David Hodgson, Sharon Castellino, Bradford Hoppe. A Survey of Children’s Oncology Group Hodgkin Lymphoma Members Regarding the Role of Radiotherapy in the Management of Pediatric Relapsed/Refractory Hodgkin Lymphoma. American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting
61. Paul Harker-Murray, MD, PhD, Brent L Wood, MD, PhD, Meenakshi Devidas, PhD, Zhinguo Chen, MS4, Tal Schecter-Finkelstein, MD, Robert J Hayashi, MD, Keith J August, MD, MS, Kimberly P Dunsmore, MD, Michelle L Hermiston, MD, PhD, Terzah Horton, MD, PhD, Yoav H Messinger, MD, Eric S Schafer, MD, MHS, Maria L Sulis, MD, Sarah L Vargas, PhD, Stuart S Winter, MD, Charlotte Wood, CCRP, Catherine M Bollard, MD, MBChB, Mignon L Loh, MD, Steve P Hunger, MD, Elizabeth A Raetz, MD, David T Teachey, MD, Intensification of chemotherapy using a modified BFM backbone for children, adolescents and young adults with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) identifies highly chemorefractory patients who benefit from allogeneic hematopoietic stem cell transplantation, Eighth Annual Pediatric Cancer Symposium: Exploring Immunotherapy in Pediatric Cancers, Milwaukee, WI, 2022
62. Hayashi RJ, Hermiston M, Teachey DT, Devidas M, Wood BL, Chen Z, , Annett R, Asselin B, August K, Cho S, Dunsmore K, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton T, Jaju AI, Lam A, Messinger YH, Miles RR, Okada N, Patel SI, Rao KW, Schafer ES, Schechter-Finkelstein T, Shimano KA, Singh N, Steele AC, Sulis ML, Vargas SL, Winter S, Wood C, Zweidler-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, and Allen, Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231. (American Society of Hematology Annual Meeting, 2022, Abstract number 2842)
63. Forlenza CJ, Rosenzweig J, Mauguen A, Buhtoiarov IN, Cuglievan B, Dave H, Deyell R, Flerlage JE, Franklin ARK, Krajewski J, Leger KJ, Marks LJ, Norris RE, Pacheco M, Willen FK, Yan AP, Harker-Murray P, Giulino-Roth L. Brentuximab Vedotin Following Autologous Transplantation in Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma. Blood Adv. 2023 Mar 10:bloodadvances.2022009323. doi: 10.1182/bloodadvances.2022009323. Epub ahead of print. PMID: 36897253.
64. Stephen Daw, Peter D. Cole, Bradford S. Hoppe, David Hodgson, Auke Beishuizen, Nathalie Garnier, Salvatore Buffardi, Maurizio Mascarin, Andrej Lissat, Alev Akyol, Russell Crowe, Ju Li, Richard A. Drachtman, Kara M. Kelly, Thierry Leblanc, Paul Harker-Murray. Response-adapted therapy with nivolumab plus brentuximab vedotin without autologous hematopoietic cell transplantation in children, adolescents, and young adults with low-risk relapsed/refractory classic Hodgkin lymphoma: CheckMate 744. (Abstract number 7515, American Society of Clinical Oncology Annual Meeting, 2023) · Selected for Poster Discussion session at ASCO, ASCO Daily News Coverage, and interview with the Video Journal of Hematology and Oncology)
65. Bradford Hoppe, Stephen Daw, Peter Cole, David Hodgson, Auke Beishuizen, Nathalie Garnier, Salvatore Buffardi, Maurizio Mascarin, Torsten Ebeling, Alev Akyol, Russell Crowe, Yan Xu, Richard Drachtman, Kara Kelly, Thierry Leblanc, Paul Harker-Murray. Consolidative radiotherapy in place of autologous stem cell transplant in patients with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) treated with nivolumab plus brentuximab vedotin: CheckMate 744. (American Society for Radiation Oncology 2023 Annual Meeting. Abstract 55690)
66. Paul Harker-Murray, Peter D. Cole, Bradford S. Hoppe, David Hodgson, Auke Beishuizen, Nathalie Garnier, Salvatore Buffardi, Maurizio Mascarin, Andrej Lissat, Alev Akyol, Russell Crowe, Ju Li, Richard A. Drachtman, Kara M. Kelly, Thierry Leblanc, Stephen Daw. Response-adapted therapy with nivolumab plus brentuximab vedotin without autologous hematopoietic cell transplantation in children, adolescents, and young adults with low-risk relapsed/refractory classic Hodgkin lymphoma: CheckMate 744. (Presented at the 2023 Medical College of Wisconsin Cancer Center Retreat, Discovery World Science & Technology Museum, Milwaukee) · Received “Best Poster Award” for category of Discovery and Developmental Therapeutics
67. Stephen Daw, Peter D. Cole, Bradford S. Hoppe, David Hodgson, Auke Beishuizen, Nathalie Garnier, Salvatore Buffardi, Maurizio Mascarin, Andrej Lissat, Alev Akyol, Russell Crowe, Ju Li, Richard A. Drachtman, Kara M. Kelly, Thierry Leblanc, Paul Harker-Murray. Response-adapted therapy with nivolumab plus brentuximab vedotin without autologous hematopoietic cell transplantation in children, adolescents, and young adults with low-risk relapsed/refractory classic Hodgkin lymphoma: CheckMate 744. (Submitted to the 2023 International Symposium on Childhood, Adolescent and Young Adult Hodgkin Lymphoma)
68. Paul Harker-Murray, Cindy Schwartz. Hodgkin Lymphoma: Past, Present, and Future. (Oral Presentation, 2024 Pediatric Cancer Symposium, Medical College of Wisconsin)

© 2025 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

Faculty Collaboration Database

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty